middle.news
Argenica Therapeutics Cuts Losses by 16% Amid Rising R&D Income
8:52am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Argenica Therapeutics Cuts Losses by 16% Amid Rising R&D Income
8:52am on Monday 2nd of June, 2025 AEST
Key Points
Loss after tax decreased 16% to $1.19 million for H1 FY2025
Other income rose 29%, driven by increased R&D tax incentive rebates
Research and development expenses slightly increased to $2.92 million
Net operating cash outflows stable at around $1.18 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE